cervical cancer
Conditions
Interventions
Case series:SHR-1210 combined with Apatinib and Paclitaxel(albumin bound)
Sponsors
Wuhan union hospital, Huazhong University of science and technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects who meet all the following criteria can be selected for this study: 1. Aged 18 ~ 70 years old, female; 2. For cervical cancer diagnosed by histology or cytology, the first-line standard treatment recommended by NCCN guidelines has been carried out, and the condition is progressing; 3. According to RECIST 1.1 standard, the patient has at least one target lesion with measurable diameter; 4. ECoG PS 0-1 point; 5. The functions of important organs shall meet the following requirements: (1) Absolute neutrophil count (ANC) >=1.5x10^9/L; (2) Platelet >=100x10^9/L; (3) Hemoglobin >=90g/L; (4) Bilirubin =50ml / min; (6) Thyroid function is normal. 6. Estimated survival time >=3 months; 7. Female subjects with fertility shall conduct urine or serum pregnancy test within 72 hours before receiving the first study drug and prove to be negative, and are willing to use effective contraceptive methods from the test period to 3 months after the last administration of shr-1210; 8. The patients voluntarily joined the study and signed the informed consent form (ICF), with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. The patient has any active autoimmune disease or has a history of autoimmune disease; 2. The patient is using immunosuppressant or systemic hormone therapy to achieve the purpose of immunosuppression (dose > 10mg / day, prednisone or other effective hormones); 3. Severe allergic reaction to other monoclonal antibodies; 4. Suffering from hypertension and can not be well controlled by antihypertensive drugs (systolic blood pressure >=140 mmHg or diastolic blood pressure >=90 mmHg); 5. There are clinical symptoms or diseases of heart that are not well controlled; 6. Abnormal coagulation function (INR > 2.0, Pt > 16S), bleeding tendency or undergoing thrombolytic or anticoagulant therapy, allowing the preventive use of low-dose aspirin and low molecular weight heparin; 7. Significant clinical bleeding symptoms or definite bleeding tendency occurred within 3 months before enrollment; 8. Routine urine examination showed that urinary protein >=+ + and it was confirmed that 24-hour urinary protein > 1.0 g; 9. The patient has active infection, unexplained fever >=38.5 degree C within 7 days before medication, or baseline leukocyte count > 15x10^9/L; 10. The patient has previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1 / PD-L1, or has previously received apatinib therapy or albumin bound paclitaxel therapy; Other patients considered unsuitable by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate (ORR); | — |
Countries
China
Contacts
Public ContactG.L.Li
Wuhan Union Hospital, Huazhong University of Science and Technology
Outcome results
None listed